What it's for (Indications)
- Perindopril + Indapamide is indicated for the treatment of essential hypertension in adults.
- This fixed-dose combination is generally prescribed for patients whose blood pressure is not adequately controlled with monotherapy of either perindopril or indapamide alone, or for initial therapy in cases where the physician determines that the potential benefits outweigh the risks of initiating treatment with a combination product.
- The combination leverages the complementary mechanisms of action of an angiotensin-converting enzyme (ACE) inhibitor and a thiazide-like diuretic, providing enhanced antihypertensive efficacy and often better tolerability than higher doses of either component alone.
- Its use is supported by clinical evidence demonstrating significant and sustained reductions in blood pressure, which is crucial for reducing the long-term risk of cardiovascular and cerebrovascular events associated with hypertension.
- Careful consideration should be given to dose titration and individual patient response, particularly in vulnerable populations.
- The decision to use this combination should be based on an assessment of the patient's overall cardiovascular risk profile and previous responses to antihypertensive agents.
- This therapeutic approach aims to achieve target blood pressure goals as defined by contemporary clinical guidelines, contributing to improved patient outcomes and quality of life for individuals managing chronic hypertension.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of Perindopril + Indapamide must be individualized based on the patient’s clinical response and tolerability, with careful consideration of the patient's renal function and hydration status. Typically, treatment is initiated with the lowest available dose, such as 2.5 mg perindopril / 0.625 mg indapamide, administered once daily. The dose can be titrated upwards, if necessary, after at least 3-4 weeks to allow for stabilization of blood pressure, to a maximum of 10 mg perindopril / 2.5 mg indapamide once daily, to achieve optimal blood pressure control while minimizing adverse effects. The medication should be taken orally, preferably in the morning and before a meal, to optimize absorption and reduce the likelihood of nocturnal diuresis. For patients with renal impairment, a careful assessment of creatinine clearance (CrCl) is essential. In patients with moderate renal impairment (CrCl 30-60 mL/min), the starting dose should be reduced, and renal function along with serum potassium levels should be closely monitored. The use of this combination is generally contraindicated in severe renal impairment (CrCl < 30 mL/min) due to the indapamide component. Close monitoring of blood pressure, electrolytes (especially potassium), and renal function (serum creatinine, blood urea nitrogen) is crucial throughout the treatment period, especially during dose adjustments or in patients with pre-existing conditions that may predispose them to electrolyte imbalances or renal dysfunction. Dosage adjustments may also be necessary in elderly patients who may have reduced renal function or be more sensitive to the hypotensive effects. |
Safety & Warnings
Common Side Effects
- Perindopril + Indapamide, while generally well-tolerated, can cause a range of side effects attributable to its individual components.
- Common side effects include dizziness, headache, fatigue, and orthostatic hypotension, particularly upon initiation of therapy or dose escalation.
- A persistent, dry, non-productive cough is a well-known class effect of ACE inhibitors like perindopril, affecting a significant proportion of patients and often leading to discontinuation.
- Gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and taste disturbance (dysgeusia) may also occur.
- Indapamide, a diuretic, can lead to electrolyte imbalances, most notably hypokalemia (low potassium), hyponatremia (low sodium), and hypomagnesemia, requiring regular monitoring.
- Hyperglycemia and hyperuricemia (which can precipitate gout attacks) are also potential metabolic side effects associated with the diuretic component.
- More serious, albeit less common, adverse effects include angioedema, a severe allergic reaction characterized by swelling of the face, lips, tongue, glottis, and/or larynx, which can be life-threatening and necessitates immediate medical attention and discontinuation of the drug.
- Renal dysfunction, including acute renal failure, can occur, especially in patients with pre-existing renal impairment, severe congestive heart failure, or renovascular hypertension.
- Other potential side effects include skin rashes, photosensitivity reactions (due to indapamide), muscle cramps, and sexual dysfunction.
- Patients should be advised to report any unusual or severe symptoms promptly to their healthcare provider.
- Regular laboratory monitoring of electrolytes, renal function, and glucose levels is essential to detect and manage these potential adverse effects effectively, ensuring patient safety and adherence to treatment.
Serious Warnings
- Black Box Warning: **FETAL TOXICITY** **Perindopril + Indapamide can cause injury and death to the developing fetus when administered to pregnant women. Discontinue Perindopril + Indapamide as soon as possible when pregnancy is detected. Drugs that act directly on the renin-angiotensin system (RAS) can cause oligohydramnios, which may result in fetal injury and/or death. This includes severe hypotension, renal failure, skull hypoplasia, anuria, and death in the developing fetus. These adverse effects are most common during the second and third trimesters of pregnancy. If Perindopril + Indapamide is inadvertently used during pregnancy, particularly during the second or third trimester, patients should be apprised of the potential hazard to the fetus. Neonates with a history of in utero exposure to an ACE inhibitor should be closely observed for hypotension, oliguria, and hyperkalemia. Furthermore, all women of childbearing potential should be made aware of the potential risks to the fetus and should use effective contraception while receiving treatment with Perindopril + Indapamide. If pregnancy is planned or suspected, treatment with Perindopril + Indapamide should be immediately discontinued, and appropriate alternative therapy should be initiated to manage hypertension.**
- Several critical warnings are associated with the use of Perindopril + Indapamide.
- Severe hypotension, particularly after the initial dose, can occur, especially in patients who are volume-depleted (e.
- g.
- , due to diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting) or have severe congestive heart failure.
- Such patients should be closely monitored, and any volume or salt depletion should be corrected before initiating treatment.
- Angioedema of the face, extremities, lips, tongue, glottis, and/or larynx has been reported with ACE inhibitors, including perindopril.
- This can occur at any time during treatment and may be life-threatening, requiring immediate cessation of the drug and appropriate medical management.
- Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk.
- Concomitant use with sacubitril/valsartan is contraindicated due to an increased risk of angioedema.
- Renal impairment, including acute renal failure, can develop, particularly in patients with pre-existing renal disease, severe congestive heart failure, renal artery stenosis (especially bilateral or in a solitary kidney), or those undergoing diuretic therapy.
- Regular monitoring of renal function is paramount.
- Hyperkalemia (elevated serum potassium) can occur, especially in patients with renal insufficiency, diabetes mellitus, or those concurrently taking potassium-sparing diuretics, potassium supplements, or other drugs that increase potassium levels.
- Indapamide can induce significant electrolyte disturbances, including hypokalemia, hyponatremia, and hypochloremic alkalosis, necessitating periodic monitoring of serum electrolytes.
- Photosensitivity reactions may occur due to the indapamide component, and patients should be advised to protect their skin from sun exposure.
- The use of Perindopril + Indapamide during surgery or anesthesia may lead to profound hypotension due to potentiation of the effects of anesthetics.
- Patients should inform their surgeon and anesthesiologist that they are taking this medication.
- Patients with a history of sulfonamide allergy should be cautioned as indapamide is a sulfonamide derivative.
- Additionally, careful consideration is warranted in patients with hepatic impairment, as diuretics can precipitate hepatic encephalopathy.
- The drug should not be used in pregnancy due to the risk of fetal toxicity, which constitutes a Black Box Warning.
How it Works (Mechanism of Action)
Perindopril + Indapamide combines two distinct antihypertensive agents that act synergistically to lower blood pressure. Perindopril is an angiotensin-converting enzyme (ACE) inhibitor. Its primary mechanism involves blocking the enzyme ACE, which is responsible for converting inactive angiotensin I into the potent vasoconstrictor angiotensin II. By inhibiting angiotensin II formation, perindopril leads to several physiological changes: it causes vasodilation by reducing peripheral vascular resistance, decreases the secretion of aldosterone (resulting in reduced sodium and water reabsorption and increased potassium excretion in the kidneys), and reduces sympathetic nervous system activity. Additionally, ACE inhibitors prevent the breakdown of bradykinin, a vasodilator, which further contributes to blood pressure reduction and may also be responsible for the common side effect of cough. Indapamide is a thiazide-like diuretic, pharmacologically distinct from traditional thiazide diuretics but sharing similar actions. It acts primarily in the cortical diluting segment of the renal tubule, where it inhibits the reabsorption of sodium and chloride ions. This inhibition leads to increased excretion of sodium, chloride, and water, resulting in a reduction in circulating plasma volume. Unlike traditional thiazides, indapamide also possesses direct vasodilatory properties on arterial smooth muscle, which contributes to its antihypertensive effect by reducing total peripheral resistance. The combination of perindopril's effects on the renin-angiotensin-aldosterone system and indapamide's diuretic and vasodilatory actions provides a comprehensive and potent approach to blood pressure control, often allowing for lower doses of each component and thereby reducing dose-dependent side effects while achieving superior efficacy compared to monotherapy.